共 50 条
- [41] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 TherapyCANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22Joseph, Richard W.Cappel, MarkGoedjen, BrentGordon, MatthewKirsch, BrandonGilstrap, CherylBagaria, SanjayJambusaria-Pahlajani, Anokhi
- [42] Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodiesJOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 555 - 559Baron, KelseyMoser, Justin C.Patel, ShivenGrossmann, Kenneth F.Colonna, Sarah, VHyngstrom, John R.
- [43] Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapyJOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (02) : 81 - 90Irwin, Debra E.Davis, BrianBell, Jill A.Galaznik, AaronGarcia-Ribas, Ignacio
- [44] Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanomaCANCER BIOLOGY & THERAPY, 2021, 22 (10-12) : 513 - 526Hughes, TashaKlairmont, MatthewSharfman, William H.Kaufman, Howard L.
- [45] Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic MelanomaCANCERS, 2020, 12 (08) : 1 - 18Asher, NethanelBen-Betzalel, GuyLev-Ari, ShakedShapira-Frommer, RonnieSteinberg-Silman, YaelGochman, NetaSchachter, JacobMeirson, TomerMarkel, Gal
- [46] Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic MelanomaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (10) : 1068 - +da Silva, Ines PiresAhmed, TasniaMcQuade, Jennifer L.Nebhan, Caroline A.Park, John J.Versluis, Judith M.Serra-Bellver, PatricioKhan, YasirSlattery, TimOberoi, Honey K.Ugurel, SelmaHaydu, Lauren E.Herbst, RudolfUtikal, JochenPfoehler, ClaudiaTerheyden, PatrickWeichenthal, MichaelGutzmer, RalfMohr, PeterRai, RajatSmith, Jessica L.Scolyer, Richard A.Arance, Ana M.Pickering, LisaLarkin, JamesLorigan, PaulBlank, Christian U.Schadendorf, DirkDavies, Michael A.Carlino, Matteo S.Johnson, Douglas B.Long, Georgina V.Lo, Serigne N.Menzies, Alexander M.
- [47] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038CANCER RESEARCH, 2017, 77Ribas, AntoniMartin-Algarra, SalvadorBhatia, ShailenderHwu, Wen-JenSlingluff, Craig L.Sharfman, William H.Hodi, F. StephenUrba, Walter J.Luke, Jason J.Haanen, John B.Callahan, Margaret K.Wolchok, Jedd D.Chasalow, Scott D.Ross-Macdonald, PetraYoung, Tina C.Qureshi, AnilaHorak, Christine E.
- [48] Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapyANNALS OF ONCOLOGY, 2019, 30Hepner, A.Carlino, M. S.Johnson, D. B.Gerard, C. L.Lo, S.Pallan, L.Silva, I. D.Michielin, O. A.Long, G. V.Menzies, A. M.
- [49] Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)Pires da Silva, InesZakria, DannyAhmed, TasniaTrojanello, ClaudiaDimitriou, FlorentiaAllayous, ClaraGerard, CamilleZimmer, LisaLo, SerigneMichielin, OlivierLebbe, CelesteMangana, JohannaAscierto, Paolo AntonioJohnson, Douglas B.Carlino, MatteoMenzies, AlexanderLong, Georgina
- [50] Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with IpilimumabCURRENT ONCOLOGY, 2022, 29 (10) : 7695 - 7704Goutam, SiddharthaStukalin, IgorEwanchuk, BenjaminSander, MichaelDing, Philip Q.Meyers, Daniel E.Heng, DanielCheung, Winson Y.Cheng, Tina